LifeStance Health Group (NASDAQ:LFST) Director Sells $42,626,750.01 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Darren Black sold 8,407,643 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the transaction, the director owned 33,524,715 shares in the company, valued at $169,970,305.05. This represents a 20.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

LifeStance Health Group Stock Performance

Shares of LFST opened at $5.55 on Friday. The company’s fifty day moving average price is $4.67 and its 200 day moving average price is $6.01. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $8.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market capitalization of $2.16 billion, a PE ratio of -111.00 and a beta of 1.13.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The business had revenue of $345.31 million for the quarter, compared to analysts’ expectations of $345.05 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on LFST. UBS Group increased their target price on shares of LifeStance Health Group from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Friday, August 8th. BTIG Research began coverage on shares of LifeStance Health Group in a report on Friday, July 25th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, Wall Street Zen upgraded shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Cim Investment Management Inc. raised its holdings in shares of LifeStance Health Group by 100.8% during the second quarter. Cim Investment Management Inc. now owns 24,734 shares of the company’s stock worth $128,000 after acquiring an additional 12,414 shares during the period. State of Wyoming grew its position in LifeStance Health Group by 31.5% in the second quarter. State of Wyoming now owns 86,629 shares of the company’s stock valued at $448,000 after purchasing an additional 20,728 shares in the last quarter. Tower Research Capital LLC TRC grew its position in LifeStance Health Group by 467.4% in the second quarter. Tower Research Capital LLC TRC now owns 20,507 shares of the company’s stock valued at $106,000 after purchasing an additional 16,893 shares in the last quarter. Vident Advisory LLC grew its position in LifeStance Health Group by 12.7% in the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares in the last quarter. Finally, Oxford Asset Management LLP grew its position in LifeStance Health Group by 5.1% in the second quarter. Oxford Asset Management LLP now owns 92,750 shares of the company’s stock valued at $480,000 after purchasing an additional 4,495 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.